MX2019010199A - El profarmaco de un inhibidor de polimerasa ns5b del virus de la hepatitis c (hcv) y metodo de produccion y aplicacion del mismo. - Google Patents

El profarmaco de un inhibidor de polimerasa ns5b del virus de la hepatitis c (hcv) y metodo de produccion y aplicacion del mismo.

Info

Publication number
MX2019010199A
MX2019010199A MX2019010199A MX2019010199A MX2019010199A MX 2019010199 A MX2019010199 A MX 2019010199A MX 2019010199 A MX2019010199 A MX 2019010199A MX 2019010199 A MX2019010199 A MX 2019010199A MX 2019010199 A MX2019010199 A MX 2019010199A
Authority
MX
Mexico
Prior art keywords
prodrug
same
producing
polymerase inhibitor
hcv ns5b
Prior art date
Application number
MX2019010199A
Other languages
English (en)
Inventor
Vasilievich Ivachtchenko Alexandre
Dmitrievich Mitkin Oleg
Original Assignee
Alla Chem Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alla Chem Llc filed Critical Alla Chem Llc
Publication of MX2019010199A publication Critical patent/MX2019010199A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a un profármaco y la aplicación del mismo para el tratamiento del virus de la hepatitis C en pacientes; el profármaco de fórmula general 1, su estereoisómero, análogo isotópicamente enriquecido, o forma cristalina o polimórfica,.
MX2019010199A 2017-02-28 2017-04-07 El profarmaco de un inhibidor de polimerasa ns5b del virus de la hepatitis c (hcv) y metodo de produccion y aplicacion del mismo. MX2019010199A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017106609A RU2644156C1 (ru) 2017-02-28 2017-02-28 Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения
PCT/RU2017/000210 WO2018160089A1 (ru) 2017-02-28 2017-04-07 Пролекарство ингибитора ns5b hcv полимеразы, способ его получения и применения

Publications (1)

Publication Number Publication Date
MX2019010199A true MX2019010199A (es) 2019-12-18

Family

ID=61173513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010199A MX2019010199A (es) 2017-02-28 2017-04-07 El profarmaco de un inhibidor de polimerasa ns5b del virus de la hepatitis c (hcv) y metodo de produccion y aplicacion del mismo.

Country Status (12)

Country Link
US (1) US10683315B2 (es)
EP (1) EP3398954B1 (es)
JP (1) JP6948401B2 (es)
KR (1) KR102467928B1 (es)
CN (1) CN110382514B (es)
BR (1) BR112019017843A2 (es)
DK (1) DK3398954T3 (es)
EA (1) EA201900320A1 (es)
HU (1) HUE050587T2 (es)
MX (1) MX2019010199A (es)
RU (1) RU2644156C1 (es)
WO (1) WO2018160089A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2659388C1 (ru) * 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02011641A (es) 2000-05-26 2004-07-30 Idenix Cayman Ltd Metodos para tatar infecciones por viurs de hepatitis delta con beta-l-2'-desoxi-nucleosidos.
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
KR20080091767A (ko) 2005-12-14 2008-10-14 씨아이피엘에이 엘티디. (테노포비어 및 라미뷰딘과 같은) 뉴클레오티드 역전사효소억제제 및 뉴클레오시드 역전사효소 억제제를 투여 단위의상이한 부분에 포함하는 약제학적 조합물
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2010028968A2 (en) 2008-09-09 2010-03-18 F. Hoffmann-La Roche Ag Polymorphs of acyl sulfonamides
CA2828326C (en) * 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
US9556216B2 (en) * 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
RU2567854C1 (ru) * 2014-11-11 2015-11-10 Александр Васильевич Иващенко Нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения

Also Published As

Publication number Publication date
CN110382514B (zh) 2023-06-02
JP2020509029A (ja) 2020-03-26
JP6948401B2 (ja) 2021-10-13
EP3398954B1 (en) 2020-06-10
WO2018160089A1 (ru) 2018-09-07
DK3398954T3 (da) 2020-07-27
KR20190140904A (ko) 2019-12-20
EP3398954A4 (en) 2019-04-17
CN110382514A (zh) 2019-10-25
BR112019017843A2 (pt) 2020-04-14
KR102467928B1 (ko) 2022-11-16
US20190382428A1 (en) 2019-12-19
RU2644156C1 (ru) 2018-02-08
HUE050587T2 (hu) 2021-01-28
EP3398954A1 (en) 2018-11-07
EA201900320A1 (ru) 2020-01-28
US10683315B2 (en) 2020-06-16

Similar Documents

Publication Publication Date Title
EA202090775A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
PH12018500931A1 (en) Hcv polymerase inhibitors
PH12016501631A1 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2016014728A (es) Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
TW201612162A (en) Azepane derivatives and methods of treating hepatitis B infections
MX2021008646A (es) Acidos carboxilicos policiclicos sustituidos, analogos de los mismos, y metodos para utilizar los mismos.
WO2016164619A3 (en) Compositions and methods for the treatment of hbv infection
MX2021007602A (es) Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b.
PH12016500320A1 (en) Cyclosporin analogues for preventing or treating hepatitis c
WO2017161133A8 (en) N-hydroxyisoquinolinedione inhibitors of hbv replication
MX2019010199A (es) El profarmaco de un inhibidor de polimerasa ns5b del virus de la hepatitis c (hcv) y metodo de produccion y aplicacion del mismo.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
EA201800388A1 (ru) Макрогетероциклические нуклеозидные производные и их аналоги, получение и применение
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
MY192374A (en) Synthesis of 2?-fluoro-6?-methylene-carbocyclic adenosine (fmca) and 2?-fluoro-6?-methylene-carbocyclic guanosine (fmcg)
MX2021006993A (es) Analogos de nucleosidos de ciclopentilo como antivirales.
WO2015191526A3 (en) Antiviral compounds
IL283039A (en) Immunological preparations for the treatment of hepatitis B
MX2021006992A (es) Análogos de nucleósidos de ciclobutilo como antivirales.